Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases

Fineline Cube Jul 6, 2026
Company Deals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

Fineline Cube Jul 6, 2026
Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company

Clinigen Expands Global Footprint with First Fully-Owned Subsidiary in Shanghai’s Free Trade Zone

Fineline Cube Jan 31, 2024

Clinigen, a UK-based medical and pharmaceutical services provider, has announced the establishment of its first...

Company Drug

European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 31, 2024

The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...

Company Deals

WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies

Fineline Cube Jan 31, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company

Shanghai Administration Imposes Hefty Fine on H&S Pharmaceutical for Substandard Drugs

Fineline Cube Jan 31, 2024

The Shanghai Municipal Medical Products Administration has disclosed that Hengshan (H&S) Pharmaceutical is under scrutiny...

Company

Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products

Fineline Cube Jan 31, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company Deals

Regeneron Pharmaceuticals Acquires 2seventy Bio to Boost Cell Therapy Capabilities

Fineline Cube Jan 31, 2024

Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the acquisition of U.S. biotechnology company 2seventy Bio Inc....

Policy / Regulatory

Hunan Province Hospitals Commit to Implementing Nationally Negotiated Drugs in Policy Seminar

Fineline Cube Jan 31, 2024

A policy seminar under the auspices of the Hunan Healthcare Security Administration bureau convened in...

Company

Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion

Fineline Cube Jan 31, 2024

Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...

Company

Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research

Fineline Cube Jan 31, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...

Company Deals

Shanghai CureGene Pharmaceutical Secures USD 14 Million in Series B Financing to Advance Cardiovascular Treatments

Fineline Cube Jan 31, 2024

Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of...

Company Deals

Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China

Fineline Cube Jan 31, 2024

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good...

Company Deals Hospital

Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center

Fineline Cube Jan 31, 2024

Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...

Company Drug

Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL

Fineline Cube Jan 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program

Fineline Cube Jan 30, 2024

Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS)...

Company Drug

Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 30, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...

Company Hospital Policy / Regulatory

Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry

Fineline Cube Jan 30, 2024

The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi...

Company Drug

AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication

Fineline Cube Jan 30, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...

Company

MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023

Fineline Cube Jan 30, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...

Company Deals

SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing

Fineline Cube Jan 30, 2024

SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD...

Company Deals

Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion

Fineline Cube Jan 30, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing...

Posts pagination

1 … 431 432 433 … 690

Recent updates

  • Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology
  • Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases
  • iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations
  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology

Company Deals

Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases

Company Deals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.